A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilmumab Followed by Nivolumab Monotherapy
Study of Anti-Tumor Activity and Potential Predictors of Response in Patients with Melanoma (Advanced Mucosal or Acral Letiginous Melanoma)
Sponsor: BMS
Enrolling: Male and Female Patients
IRB Number: AAAR1551
U.S. Govt. ID: NCT02978443
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out which participants with melanoma respond best to nivolumab and ipilimumab treatment and to identify tumor and blood based markers that may predict response to the combination. This study is asking that participants submit tumor tissue samples from their initial tumor specimen and blood samples before they receive treatment with nivolumab and ipilimumab. This study is to determine which patients are most appropriate for this treatment and potential factors that might suggest patients should be considered for a different treatment.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with melanoma (mucosal melanoma or acral lentiginous melanoma)?? Yes No
Are you willing to donate a small amount of blood prior to treatment and during treatment? Yes No
Are you willing and able to give informed consent prior to initiation of therapy? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator